AYTU BIOPHARMA, INC Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
AYTU BIOPHARMA, INC (AYTU) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $3.20 million as of 2018-06-11, per its 10-K filed 2018-09-06.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2018-09-06
- 2018-06-11: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $3.20M.
- 2015-05-20: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $2.39M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|---|---|
| 2018-06-11 | $3.20M 10-K · filed 2018-09-06 |
| 2015-05-20 | $2.39M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |